SciSparc's AI and quantum pivot drives gains, Tourette drug advances
Agentic AI pivot opens new growth path SciSparc's board decided to target the agentic AI market and formed an AI and cybersecurity advisory board, while evaluating deals with several AI companies. This signals a strategic shift toward a high-growth tech sector, which can lift SPRC's price by attracting investors betting on a new business line beyond biotech.
This is a new strategic direction that changes the company's story and investor appeal.
Quantum workflow validation sparks 70% surge NeuroThera Labs validated a quantum sampling workflow for clinical trial data on an S&P 500 company's platform, and SPRC shares jumped 70.5% to $9.09. The move shows investors are rewarding the quantum computing angle, though such sharp one-day spikes can fade without follow-through.
This was the period's biggest price catalyst and shows how the quantum story is being received.
Tourette drug advances with Phase IIb and FDA orphan bid NeuroThera started a Phase IIb trial of SCI-110 for Tourette Syndrome at Hannover Medical School and is seeking FDA Orphan Drug Designation, hiring a government affairs firm. Progress on the core drug candidate supports SPRC's value by raising the odds of a future approved product.
Clinical and regulatory progress on the main drug candidate is a fundamental value driver.
CliniQuantum reports 16.8-fold simulation speedup CliniQuantum, majority-owned by NeuroThera, reported a 16.8-fold speedup in quantum simulation on gene data using a GPU. The company itself notes this benchmark does not prove clinical value, so the news supports the tech narrative but is not yet a proven medical or revenue breakthrough.
This is the latest quantum milestone that keeps the technology story alive for investors.